Despite analyses of four samples identifying ATRX mutations as a significant molecular factor in lower-grade gliomas [35], ALT activation has been associated with ATRX deficiency in only 14–35% of high-grade pediatric gliomas [36]. The gene discussed is ATRX; the disease is central nervous system cancer.